COPENHAGEN (Reuters) - Novo Nordisk NOVOb.CO posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs.
Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. It said operating profit rose 9% in the last quarter, slightly below analysts’ forecasts.
The world’s largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
Sales of its new once-weekly injectable treatment, branded Ozempic, reached 6,872 million Danish crowns ($1.03 billion) for the first nine months, attaining blockbuster status.
Ozempic’s third-quarter sales came in 11% stronger than expected, said Jefferies analysts
The new drug is a competitor of Eli Lilly’s Trulicity. Both drugs belong to the GLP-1 drug class, which imitate an intestinal hormone that stimulates the production of insulin.
These drugs are more expensive but make up a growing share of the diabetes market, as they have proved effective in reducing diabetes patients’ blood glucose levels and weight.
“We believe we have the better product both in terms of glucose lowering, weight (reduction) and the cardiovascular safety profile,” said chief financial officer Karsten Munk Knudsen, referring to clinical trials.
“Our sales reps have what they need to go into the market and compete vis-a-vis with Trulicity,” he said, adding that Novo is taking market share from Eli Lilly in the GLP-1 market.
Competition in the GLP-1 space is set to further increase as Novo recently won approval for its once-daily oral pill Rybelsus, which is aimed at patients with an aversion to needles used to deliver other diabetes treatments.
Third-quarter Trulicity sales fell short of Wall Street expectations with some analysts suggesting they were likely hurt by Lilly’s efforts to defend its market share against the upcoming launch of Rybelsus.
Novo’s third-quarter operating profit came in at 12.9 billion Danish crowns ($1.93 billion), slightly below the 13.1 billion forecast in a Refinitiv poll partly due to higher impairment charges..
Depreciation, amortization and impairment losses this year are now seen 1 billion crowns higher than previously anticipated, Novo said.
Sales of Novo’s GLP-1 drugs grew 28%, while total insulin sales fell 1%.
Reporting by Stine Jacobsen; editing by Shri Navaratnam, Jason Neely and Jan Harvey
Our Standards: The Thomson Reuters Trust Principles.